Raji-Null Cells
-
Cat.code:
raji-null
- Documents
ABOUT
Control Human B-cell line
Raji-Null cells were developed from the human Raji cell line. Raji-Null cells constitutively express different antigens at their cell surface that can be targeted by specific antibodies, notably to induce antibody-dependent cellular cytotoxicity (ADCC).
-Human CD20 is highly expressed by Raji cells. It has no known natural ligand and is thought to act as calcium channel enabling optimal B-cell responses [1]. Human CD20 is a clinically-relevant target in mAb-mediated therapy (rituximab, ofatumumab, obinutuzumab) for non-Hodgkin's B cell lymphoma or chronic lymphocytic leukemia [2].
-Human CD19 is highly expressed by Raji cells. It acts as a co-receptor decreasing the threshold for antigen B-cell receptor (BCR)-dependent stimulation [1]. Human CD19 is a clinical target for anti-hCD19-CD3 bis-specific antibodies (blinatumomab) in non Hodgkin's B cell lymphoma [3].
- Human PD-L1 (programmed cell death ligand 1; also known as CD274 or B7-H1) is expressed at low levels by Raji cells. This transmembrane protein is expressed by hematopoietic and nonhematopoietic cells and is induced by pro-inflammatory cytokines, such as in the tumor microenvironment [4]. Human PD-L1 is a clinically-relevant target in mAb-mediated therapy (atezolizumab, durvalumab, avelumab) for a wide range of cancers [4].
Features of Raji-Null cells:
- Constitutive expression of CD19 and CD20 at the cell surface
- Constitutive low expression of PD-L1 at the cell surface
- Stable expression of a resistance gene to Blasticidin
Applications for Raji-Null cells:
- ADCC target cells using anti-hCD19, anti-hCD20, anti-hPD-L1 Abs
- Negative control target cells in ADCC assays using monoclonal Abs other than anti-hCD19, anti-hCD20, anti-hPD-L1 Abs
- Target cells for anti-hCD19-CD3 bispecific Abs
Validation of Raji-Null cells:
- Functionally tested as target cells in ADCC assays using anti-human CD20 monoclonal Abs and Jurkat-Lucia™ NFAT-CD16 cells
- Functionally tested as negative control target cells in ADCC assays using monoclonal Abs other than anti-hCD20 (e.g. anti-hCTLA-4 or anti-hPD-1 Abs)
- Functionally tested as target cells in T-cell activation assay using anti-hCD19-CD3 bi-specific Ab and Jurkat-Lucia™ NFAT cells.
References:
1. Bae J. et al. 2005. Identification of CD19 and CD20 peptides for the induction of antigen-specific CTLs against B-cell malignancies. Clin. Cancer. Res. 11:1629-38.
2. Almagro J.C. et al. 2018. Progress and challenges in the development of antibodies for cancer therapy. Front. Immunol. 8:1751.
3. Bargou R. et al. 2008. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 321(5891):974-7.
4. Ribas A. and Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.
Disclaimer: These cells are for internal research use only and are covered by a Limited Use License (See Terms and Conditions). Additional rights may be available.
SPECIFICATIONS
Specifications
CD19, CD20, PD-L1
Human
ADCC induction cellular assays, T-cell activation cellular assays, Flow cytometry
Verified using Plasmotest™
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Raji-Null Cells
-
Cat code:raji-null
-
Quantity:3-7 x 10^6 cells
- 1 ml of Blasticidin (10 mg/ml)
- 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria and fungi.
Shipping & Storage
- Shipping method: Dry ice
- Liquid nitrogen vapor
Storage:
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?